CURRICULUM VITAE – Lukas Kenner

Name and Address: Lukas Kenner, ao. Univ. Prof. Dr. Med. univ.
Institute for Cancer Research (LBI-CR)
Währinger Str. 13a, A-1090 Vienna, Austria
Phone: (+43-1)4016071210 Fax: (+43-1)40160931300
Clinical Institute of Pathology, Medical University Vienna
Währingergürtel 18-20, 1090 Vienna, Austria
Phone: (+43-1)-40400 3650 Fax: (+43-1)-40400 3707
E-mail: lukas.kenner@meduniwien.ac.at
Date of Birth: October 8th, 1965, Erlangen, Germany

Education & Career

1986-1991 University of Graz, Faculty of Medicine, Graz, Austria
1992-1994 University for Music, Konzertfach Violin, Graz
1991 Doctor medicinae (MD)
1992-1995 University Hospital Graz, Institute of Pathology, Postdoc and "Otto Loewi" Scholarship with Prof. H Denk
1995-1997 Resident, University Hospital Graz
1997-2001 Assistenzarzt, University Hospital Graz, Institute of Pathology. Education in general Pathology, Haematopathology and Gastroenteropathology with a focus on Hepatopathology
2000 Spezialisation on Haematopathology at the Pathology Institute, Free University Berlin (Prof. H. Stein)
2001 Habilitation (Venia docendi), Medical Faculty, Graz, Austria: "Lehrbefugnis for Pathology and Molecular Pathology", Title: Altered microtubule-associated tau messenger RNA isoform expression in livers of griseofulvin- and 3,5-diethoxycarbonyl-1, 4-dihydrocollidine-treated mice.
2001 Board Registration for Pathology
2001-2004 Head of the Histology Lab (IMP) and Postdoc, Institute for Molecular Pathology (IMP) with Prof. Erwin F. Wagner, Vienna, Austria
2005-2006 Consultant for Mouse Pathology for the IMP and the IMBA, Vienna
2004 Formation of the Ludwig Boltzmann Institute for Cancer Research (LBI-CR) and nomination as Group leader, contract negotiations in summer 2005
2010 Board Registration for Cytological Diagnostics
2012 Deputy Director of the **LBI-CR** (annual budget approx. 2.5 Mill. €)

Current positions

2004 to date ao. Univ. Prof. for Pathology and Groupleader at the Department of Clinical Pathology (CIP), Medical University of Vienna
2005 to date Keyresearcher and head of the Histology Laboratory at the LBI-CR
2012 to date: Deputy Director of the LBI-CR

Honors, Fellowships and Awards

Fellowship 'Pro Scientia' 1989-1992,
Otto-Loewi Scholarship, Austrian science foundation 1993 to 1994,
Research price of the Austrian Society of Nephrology 1995,
Research prize of the Hoechst–Foundation 1996,
Rokitansky award of the Austrian Society of Pathology 2004,
Sanofi-Aventis Price 2010,
Rokitansky award of the Austrian Society of Pathology 2010
Keystone Scholarship 2011,
Science und Innovations price of the German Society for Hematology und Oncology (DGHO) 2011.
Young Scientist Association (YSA) Prize for the Best Publication of the Medical University Vienna 2012.
Prize of the Comprehensive Cancer Center Drug and Target Screening Unit (DTSU) 2012.
Prize of the Central European Society for Anticancer Drug Research (CESAR) for discovering a novel therapeutic strategy for highly malignant T-cell Lymphomas 2013.

Responsibilities in Scientific Societies:
2005 to date Member of the Austrian Society of Pathology
2007 to date Corresponding Member of the Pontifical Academy Pro Vita (PAV), Vatican State
2009 to date Member of the American Association of Cancer Research (AACR)
2009 to date Member of the Bioethikommission of the Austrian Prime Minister
2009 founding member of the European Research Initiative for ALCL (ERIA)

Current Positions, Administrative and Management Activities

LK heads a group at the LBI-CR, which is funded by the Ludwig Boltzmann Society (LBG) and five partner institutions: the Medical University Vienna, the Institute of Molecular Pathology, the Children´s Cancer Research Centre, Tissue Gnostics and the University of Veterinary Medicine, Vienna. In addition, **LK** leads a group at the clinical Institute of Pathology at the MUV. For additional funding, **LK** managed to get thirdparty grants from the following fundig Agencies:

Grants Awarded

Grant	Grant holder	€/total	Funding period
FWF[#]	**LK**	**350.000**	**7/2013-6/2016**
ONKOTYROL[&]	**LK**	**120.000**	**4/2013-3/2015**
GEN-AU Inflammobiota[$]	**LK**	**240.000**	**5/2009-3/2013**
Novus Sanguis*	**LK**	**70.000**	**7/2008 - 5/2010**
FWF[##]	**LK**	**195.000**	**4/2006-3/2009**
Krebshilfe Austria[§]	**LK**	**20.000**	**2/2001-3/2003**
Jubiläumsfonds der Austrian Nationalbank**	**LK**	**20.000**	**12/1998-11/2000**
Otto Loewi Stipendium[###]	**LK**	**20.000**	**10/1993-9/1994**
Total acquired external grant money of applicant	**LK**	**1.035.000**	**10/1993-3/2015**

Summary of external research funds acquired by LK

[#] **FWF:** Genetic dissection of IL-6 signaling in prostate cancerogenesis
[&] **ONKOTYROL** Role of Medium-Chain Triacylglycerols in Prostate cancer development
[$] **GEN-AU** Inflammobiota: JAK-STAT in Inflammatory Bowel disease
*** Novus Sanguis:** JAK-STAT-in stem cell development
[##] **FWF:** Role of JunB for Lymphoma development
[§] **Krebshilfe Austria**, "cDNA-Arrays" für die Auswertung von diagnostischen und prognostischen Parametern bei Non-Hodgkin-Lymphomen
**** JF ÖNB:** Expression und functional importance of p62 in hepatocellular carcinomas
[###] **OLS:** Investigation of the pathogenetic principels in liver and central nervous system
.

Managerial responsibilities:
a) since 2004 at the Clinical Institute of Pathology (CIP):
LK heads a group were he professionally trained 1 PostDoc (Pamina Pflegerl) 1 PhD Student (Daniela Laimer) and 3 Diploma Students (Nora Dzuck, Lisa Grabner and Merima Herac). Currently 1 PhD student (Osman Askoy) and 3 Diploma students ar being trained in LK's Lab (Lena Amentisch, Tine Vollheim and Tanja Limberger). In the the past eight years **LK** has enjoyed the responsibility for the personnel, financial and scientific management his group at the CIP as well as for the dissemination of its scientific results. The soft skills of **LK** are reflected by ability to professionally train and positively interact with his coworkers and students. In addition **LK** effectively interacted and collaborated with a large number of national and international scientific partners and the members of the LBI Partner Board and SAB members. Furthermore **LK** established fruitful collaborations with the industry such as TissueGnostics and Baxter-Austria.

b) since 2005 at the LBI-CR:
LK is founding member of the LBI-CR together with Richard Morrigl, Dagmar Stoiber, Robert Eferl, Johannes Schmid, and Emilio Casanova. **LK** is Groupleader at the LBI-CR and has three positions (Michaela Schlederer, BMA Jelena Marjanovic, BMA and Jan Pencik, PhD). **LK** is responsible for the professional training and scientific education of his coworkers. Since 2012 he is deputy director of the LBI-CR and as such takes part in the detailed plan to merge the LBI-CR with its partner universities.
LK heads the Histology Lab at the LBI-CR and is responsible for the organisation and the budget of this Lab. In addition he teaches the members of the LBI-CR in tissue processing and pathohistological skills.
LK takes part in the weekly teamleader meeting at the LBI-CR which takes responsibility for all decisions in financial, organisatorial and scientific matters of the Institute with its 30 employees and an annual budget of about 2.4 Million Euros (including third-party grants).
LK also organizes the annual evaluation of the LBI-CR by a Scientific Advisory Board (SAB), which has five international members, as well as the additional external evaluations which were undertaken in 2008 and 2011.
LK is responsible for all communications with the partner company TissueGnostics, were he does professional training programs of the employees in quality management and is also responsible for EN ISO 13485:2003 certification of TG's products according to the *In Vitro* Diagnostic (IVD) guideline.
LK is Deputy Director of the LBI-CR since 1/2012.

Clinical skills and duties:
LK serves as a board certified **clinical pathologist** and cytopathologist, after 8 years of broad and international pathology training. **LK** gains broad expertise for **laboratory animal pathology**.
LK provides unique expertise, not the least due to his critical dual position as a Prof. for human pathology at the CIP (MUV) and as head of the Mouse Histology Lab at the LBI-CR to do comparative pathology. The applicant has access to the Tissue Bank at the CIP/AKH Vienna with more than 3 Million fully annotated patient samples, where the clinical and scientific data are well documented to serve for comparative translational medicine studies. This is best exemplified by

the invitation and participation of additional grant money financed by Onkotyrol, GenAU, FWF, OeNB or international funding Societies where LK is frequently asked for expertise leading to international publications in high ranking Journals.

Responsibilities in the public health service:
Since 2009: **LK** becomes member of the „Bioethikkommission of the Austrian Primeminister“ at the PrimeMinister's office Vienna.
Since 2008: **LK** becomes member of the “wissenschaftlichen Ausschusses der Gentechnik Kommission für Freisetzungen und Inverkehrbringen“ (WAFI) of the Austrian Ministry of Health.

Organisation of Scientific Events:
2010-13: four annual ERIA conferences in Salzburg, Vienna, Cambridge and Heidelberg.
Since 2005: Seminar series at the LBI-CR top Scientists from around the globe such as T. Look (Dana-Farber Cancer Institute, Boston); S. Gerson (Case University, Cleveland); A. Aguzzi (Universität Zürich); A. Östman (Karolinska Institut, Stockholm); P. Heinrich (Universität Freiburg), R. Rose-John (Universität Kiel) u.v.a.
Since 2007: monthly seminar series at the CIP with prominent Austrian Scientists such as M. Müller (VetMedUni); B. Dickson (IMP); M. Sebilia (CCC/MUV); V. Sexl (VetMedUni), A. Rees (Marie-Curie Professor/MUV); J. Penninger (IMBA) etc.

Selected invited talks (last 3 years):

Host	**Institute/Conference**	**Date**
Peter Valent	Austian Society for Haematology & Oncology, in Linz, Austria. **Plenary Talk**	4/13
Stefan Rose-John	4th cluster ,Symposium Inflammation and Interfaces, Hamburg, Germany, **Key Note Lecture**	2/13
Richard Greil	Pracelsus University Sazburg, Austria **Monthly invited speakers seminar series**	2/13
Martin Röcken	University Tübingen, Germany, **Monthly invited speakers seminar series**	1/13
Christoph Zielinski	Comprehensive Cancer Center (CCC), MUV Vienna **Key Note Lecture**	12/12
Heinrich Kovar	CCRI, Vienna, Austria **Monthly invited speakers seminar series**	2/12
Raphaella Sordella	Cold Spring Harbor Laboratory (CSHL), NY, USA, **Key Note Lecture**	12/11
Lukas Kenner	2nd meeting European Research Initiative on ALK-related malignancies, Vienna, Austria	06/11
Mariusz Ratajczak	1st Baltic Stemcell meeting, Stettin, Poland, **Key Note Lecture**	05/11
William Tse	University of West Virginia, Morgantown, USA **Monthly invited speakers seminar series**	3/11
Gustavo Leone	State University Ohio, Comprehensive Cancer Center, **Key Note Lecture**	12/10
Olaf Merkel	Inaugural meeting European Research Initiative on ALK-related malignancies, Salzburg, Austria	6/10
Eliane Gluckman	2nd International Congress on Stem Cell Research, Monaco, **Key Note Lecture**	11/09
Greg Hannon	Cold Spring Harbor Laboratory (CSHL), NY, USA, **Key Note Lecture**	05/09

Reviewer, Evaluator and Advisory Function Overview
Invited as **Expert Reviewer** for Journals: American Journal of Pathology, EMBO Journal, Cancer Research, Leukaemia, PlosOne, Cancer letters, Experimental Haematology, Annals of Haematology, Molecular Neurobiology, Nephron, British Journal of Urology, International Journal

of Cancer, Stem Cell Reviews and Reports. Invited also as an **External Advisory Reviewer for mgrant funding agencies:** the Deutsche Forschungsgemeinschaft (DFG, Germany), the Landesexzellenzinitiative Hamburg (Germany), the Austrian National Bank (OeNB), the Bürgermeisterfonds der Stadt Wien, the Niederöstereichische Forschungs- und Bildungsges.m.b.H. (NFB), **Advisory Consultant** of the Bioethikkomission of the Austrian Chancellor at the Bundeskanzleramt, the wissenschaftlicher Ausschuss für Freisetzungen und Inverkehrbringen von GVO (WAFI, Austrian Ministry of Health), for Baxter Austria, and the Institute for Molecular Pathology (IMP) Vienna.

Patents:

2007 Patenting of the Multi-hit Mouse Technology "Development of transgenic mouse models for cooperative mutations in cancer development"

2009 Patenting of a novel application of PDGFRbeta blockers for cancer therapy "New use of PDGFRbeta inhibitors" (International Patent Nr. EP09171469.1.)

Peer-Reviewed Publications

Cumulative Impact Factor Total (2008-2013): **740.28**
Hirsch Factor: **24**
70 Original Articles, 9 Reviews and 2 Book Chapters

Original Articles

Summary accepted publications:	**n=70**
Cumulative Impact Factor Total (1993-2013):	**740.28**
Average Impact Factor/Original Article (excluding reviews/books): (2008 up to present, **no reviews counted**)	**10.58**

Chronologic List (Present to Past):

Cumulative Impact Factor **2013**	**22.249**
Cumulative Impact Factor **2012**	**84.276**
Cumulative Impact Factor **2011**	**28.297**
Cumulative Impact Factor **2010**	**116.997**
Cumulative Impact Factor **2009**	**43.634**
Cumulative Impact Factor **2008**	**39.067**
Cumulative Impact Factor **2007**	**45.430**
Cumulative Impact Factor **2006**	**2.923**
Cumulative Impact Factor **2005**	**63.132 (own group)**
Cumulative Impact Factor **2004**	**28.674**
Cumulative Impact Factor **2003**	**56.503**
Cumulative Impact Factor **2002**	**5.570**
Cumulative Impact Factor **2001**	**12.815 (Habilitation)**
Cumulative Impact Factor **2000**	**11.144**
Cumulative Impact Factor **1999**	**90.712**
Cumulative Impact Factor **1998**	**40.992**
Cumulative Impact Factor **1997**	**11.675**
Cumulative Impact Factor **1994**	**17.560**
Cumulative Impact Factor **1993**	**13.323**

Original Articles (1-72)

- Rao S, Tortola S, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramek D, Komnenovic V, Sigl V, Aumayr K, Schmauss G, Fellner N, Handschuh S, Glösmann M, Pasierbek P, Schlederer M, Resch GP, Ma Y, Yang H, Popper H, **Kenner L**, Kroemer G, and Penninger JM. A dual role for autophagy in a murine model of lung cancer. ***Nat. Commun.*** in press 2013 **[Impact Factor: 10.015]**

- Urich T, Berry D, Rauch I, Rennisch I, Schwab C, Ramesmayer J, Hainzl E, Heider S, Decker T, **Kenner L**, Müller M, Strobl B, Wagner M, Schleper C, and Loy A Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery ***ISME J.*** in press 2013 **[Impact Factor: 8.9]**

- Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M, Schiefer AI, Reichart U, Mayerhofer M, Hoeller C, Zöchbauer-Müller S, Kerjaschki D, Bock C, **Kenner L**, Hoefler G, Freissmuth M, Green AR, Moriggl R, Busslinger M, Malumbres M, Sexl V. ***Cancer Cell*** 24(2):167-81. DOI: 10.1016/j.ccr.2013.07.012 **[Impact Factor: 24.8]**

- Gattelli A, Nalvarte I, Boulay A, Roloff1 TC, Schreiber M, Carragher N, Macleod KK, SchledererM, Lienhard S, **Kenner L**, Torres-Arzayus MI and Hynes NE. Ret inhibition decreases metastatic potential by blocking migration of estrogen receptor positive breast cancer models. ***EMBO Mol. Med***. 2013 (9):1335-50. doi: 10.1002/emmm.201302625. **[Impact Factor: 7.8]**

- Nagarajan P, Ge Z, Sirbu B, Doughty C, Agudelo Garcia PA, Schlederer M, Annunziato AT, Cortez D, **Kenner L**, Parthun MR. Histone acetyl transferase 1 is essential for Mammalian development, genome stability, and the processing of newly synthesized histones h3 and h4. ***PLoS Genet.*** 2013 9(6):e1003518. doi: 10.1371/journal.pgen.1003518. Epub 2013**. [Impact Factor: 8.69]**

- McGuckin CP, Jurga M, Miller AM, Sarnowska A, Wiedner M, Boyle NT, Lynch MA, Jablonska A, Drela K, Lukomska B, Domanska-Janik K, **Kenner L**, Moriggl R, Degoul O, Perruisseau-Carrier C, Forraz N. ***Arch Biochem Biophys.*** 2013 534(1-2):88-97. doi: 10.1016/j.abb.2013.02.005. Epub 2013 **[Impact Factor: 3.37]**

- Unger C, Popescu R, Giessrigl B, Laimer D, Heider S, Seelinger M, Diaz R, Wallnöfer B, Egger G, Hassler M, Knöfler M, Saleh L, Sahin E, Grusch M, Fritzer-Szekeres M, Dolznig H, Frisch R, **Kenner L**, Kopp B, Krupitza G. The dichloromethane extract of the ethnomedicinal plant Neurolaena lobata inhibits NPM/ALK expression which is causal for anaplastic large cell lymphomagenesis. ***Int J Oncol.*** 42(1):338-48. doi: 10.3892/ijo.2012.1690. 2013. **[Impact Factor: 2.7]**

- Jurga M, Miller AM, Sarnowska A, Wiedner M, Boyle NT, Lynch MA, Jablonska A, Drela K, Lukomska B, Domanska-Janik K, **Kenner L**, Moriggl R, Perruisseau-Carrier C, Forraz N, McGuckin CP. Ischemic brain injury: a consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction. ***Archives of Biochemistry and Biophysics***, in press 2013 **[Impact Factor: 3.4]**

- Unger C, Popescu R, Giessrigl B, Laimer D, Heider S, Seelinger M, Diaz R, Wallnöfer B, Egger G, Hassler M, Knöfler M, Saleh L, Sahin E, Grusch M, Fritzer-Szekeres M, Dolznig H, Frisch R, **Kenner L**, Kopp B, Krupitza G. The dichloromethane extract of the ethnomedicinal plant Neurolaena lobata inhibits NPM/ALK expression which is causal for

anaplastic large cell lymphomagenesis. ***Int J Oncol.*** 42(1):338-48. 2013 **[Impact Factor: 2.7]**

- PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, **Kenner L** ***Nat Med.*** 11:1699-704 2012 [**Impact Factor: 22.9]**

- Musteanu M, Blaas L, Zenz R, Svinka J, Hoffmann T, Grabner B, Schramek D, Kantner H, Müller M, Kolbe T, Rülicke T, Moriggl R, **Kenner L**, Stoiber D, Penninger J, Popper H, Casanova E and Eferl R A Multi-Hit mouse model to identify cooperating Ras effector pathways in lung cancer. ***Nat Methods*** 9:897-900. 2012. [**Impact Factor: 23.9**]

- Klymiuk I, **Kenner L**, Adler T, Busch DH, Boersma A, Irmler M, Gailus-Durner V, Fuchs H, Leitner N, Müller M, Kühn R, Schlederer M, Treise I, Hrabe de Angelis M, Beckers J. In Vivo Functional Requirement of the Mouse Ifitm1 Gene for Germ Cell Development, Interferon Mediated Immune Response and Somitogenesis. ***PloS One*** 7(10): e44609. doi:10.1371. 2012. [**Impact Factor: 3.7**]

- Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, Denk U, Hofbauer JP, Egle A, Scheideler M, Schlederer M, Steurer M, **Kenner L**, Greil R. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. ***Leukemia*** 12:2508-16 2012. [Epub ahead of print] [**Impact Factor: 10.2**]

- Tarnowski M, Schneider G, Amann G, Clark G, Houghton P, Barr FG, **Kenner L**, Ratajczak MZ, Kucia M. RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas. ***Int J Oncol.*** 3:995-1004 2012 [**Impact Factor: 2.7]**

- Berry D, Schwab C, Milinovich G, Reichert J, Ben Mahfoudh K, Decker T, Engel M, Hai B, Hainzl E, Heider S, Kenner L, Müller M, Rauch I, Strobl B, Wagner M, Schleper C, Urich T, Loy A. Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ***ISME J.*** 11:2091-106 2012. [**Impact Factor: 8.9**]

- Hadzijusufovic E, Peter B, Herrmann H, Rülicke T, Cerny-Reiterer S, Schuch K, **Kenner L**, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl WF, Willmann M, Valent P. NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. ***Allergy*** 67(7):858-68. Epub 2012. [**Impact Factor: 5.9]**

- Friedbichler K, Themanns M, Mueller KM, Schlederer M, Kornfeld JW, Terracciano LM, Kozlov AV, Haindl S, **Kenner L**, Kolbe T, Mueller M, Snibson KJ, Heim MH & Moriggl R. Growth hormone-induced Stat5 signaling causes gigantism, inflammation and premature death but protects mice from aggressive liver cancer. ***Hepatology***, 55(3):941-52 2012 [**Impact Factor: 12.0**]

- Tarnowski M, Schneider G, Amann G, Clark G, Houghton P, Barr FG, **Kenner L**, Ratajczak MZ, Kucia M. RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas. ***Int J Oncol.*** 41(3):995-1004 2012. [**Impact Factor: 2.7**].

- Mueller KM, Kornfeld JW, Friedbichler K, Blaas L, Egger G, Esterbauer H, Hasselblatt P, Schlederer M, Haindl S, Wagner KU, Engblom D, Haemmerle G, Kratky D, Sexl V, **Kenner L**, Kozlov AV, Terraciano L, Zechner R, Schuetz G, Casanova E, Pospisilik JA, Heim MH & **Moriggl R**. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinomas in mice. ***Hepatology***, 54:1398-409 2011 [**Impact Factor: 12.0**]

- Pinent M, Prokesch A, Hackl H, Voshol PJ, Klatzer A, Walenta E, Panzenboeck U, **Kenner L**, Trajanoski Z, Hoefler G, Bogner-Strauss JG. Adipose triglyceride lipase and hormone-sensitive lipase are involved in fat loss in JunB-deficient mice. ***Endocrinology*** 152(7):2678-89 2011. [**Impact Factor: 4.7**]

- Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Hrabé de Angelis M, Schlederer M, Mair M, Kenner L, Plutzky J, Zeyda M, Stulnig TM. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. ***Diabetologia*** 54(8):2132-42 2011. [**Impact Factor: 6.5**]

- Jurkin J., Zupkovitz G., Lagger S., Grausenburger R., Hagelkruys A., **Kenner L.**, Seiser C. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. ***Cell Cycle*** 10(3):406-12 2011. [**Impact Factor: 5.2**]

- Lagger S., Meunier D., Mikula M., Brunmeir R., Schlederer M., Artaker M., Pusch O., Egger G., Hagelkruys A., Mikulits W., Weitzer G., Muellner E.W., Susani M., Seiser Ch. ***** and **Kenner L.** * Crucial function of Histone Deacetylase 1 (HDAC 1) for differentiation of Teratomas in mice and humans. ***EMBO J.*** 29(23):3992-4007 2010. [**Impact Factor: 9.8**] ***equally contributed**

- Schramek D, Leibbrandt A, Sigl V, **Kenner L**, Hanada R, Joshi PA, Pospisilik JA, Lee H, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, and Penninger JM The osteoclast differentiation factors RANKL/RANK control development of progestin-driven mammary cancer. ***Nature*** 468(7320):98-102 2010. [**Impact Factor: 38.6**]

- Merkel O, Hamacher F., Laimer D, Trajanoski Z, Scheideler M, Egger G,. Hassler MR, Thallinger C, Schmatz A, Turner SD, Greil R and **Kenner L** Identification of differential and functionally active miRNAs in both ALK^+ and ALK^- anaplastic large cell lymphoma. ***PNAS*** 107(37):16228-33 2010. [**Impact Factor: 9.7**]

- Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, **Kenner L,** Sordella R TGF-{beta} IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. ***PNAS*** 107(35):15535-40 2010. [**Impact Factor: 9.7**]

- Blaas L, Kornfeld JW, Schramek D, Musteanu M, Zollner G, Gumhold J, van Zijl F, Schneller D, Esterbauer H, Egger G, Mair M, **Kenner L**, Mikulits W, Eferl R, Moriggl R, Penninger J, Trauner M, Casanova E Disruption of the growth hormone-signal transducer and activator of transcription 5-insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. ***Hepatology*** 51(4):1319-26 2010. [**Impact Factor: 12.0**]

- Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, Säemann MD, Geyeregger R, Schlederer M, **Kenner L**, Stulnig TM Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. ***Diabetes*** 59(4):935-46 2010. [**Impact Factor: 7.9**]

- Mair M, Zollner G, Schneller D, Musteanu M, Fickert P, Gumhold J, Schuster C, Fuchsbichler A, Bilban M, Tauber S, Esterbauer H, **Kenner L**, Poli V, Blaas L, Kornfeld JW, Casanova E, Mikulits W, Trauner M, Eferl R Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. ***Gastroenterology*** 138(7):2499-508 2010. [**Impact Factor: 12.8**]

- Meixner A., Karreth F., **Kenner L.,** Penninger J.M., Wagner E.F. Jun and JunD-dependent functions in cell proliferation and stress response. ***Cell Death Differ*** 17(9):1409-19 2010 [**Impact Factor: 8.4**]

- Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, Esterbauer H, Mueller M, Casanova E, **Kenner L**, Poli V, Eferl R Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. ***Gastroenterology.*** 138(3):1003-11 2010 [**Impact Factor: 12.8**]

- Pflegerl P, Vesely P, Hantusch B, Schlederer M, Zenz R, Janig E, Steiner G, Meixner A, Petzelbauer P, Wolf P, Soleiman A, Egger G, Moriggl R, Kishimoto T, Wagner EF **Kenner L** Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. ***PNAS*** 106(48):20423-8 2009´. [**Impact Factor: 9.7**]

- Agrelo R, Souabni A, Novatchkova M, Haslinger Ch, Komnenovic V, Kishimito H, Gresh L, Kohwi Shigematsu T, **Kenner L**, Wutz A SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. ***Dev Cell*** 16(4):507-16 2009 [**Impact Factor: 12.7**]

- Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Culig Z* **Kenner L*** Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. ***Cancer Res*** 69(18):7375-84 2009 ***equally contributed.** [**Impact Factor: 8.7**]

- Malinowska K, Cavarretta IT, Culig Z* and **Kenner L*** Identification of μ-crystallin (crym) as an androgen-regulated gene in human prostate cancer. ***Prostate*** 69(10):1109-18 2009 ***equally contributed.** [**Impact Factor: 3.8**]

- Neuwirt H., Puhr M., Susani M., Doppler W., Marcias G., Santer F.R., Rauch V., Brugger M., Hobisch A., Culig Z* and **Kenner L.***. Suppressor of Cytokine Signaling (SOCS)-1 is Expressed in Human Prostate Cancer and Exerts Growth-inhibitory Function through Down-regulation of Cyclins and Cyclin-dependent Kinases. ***Am J Pathol*** 174(5):1921-30 2009 ***equally contributed.** [**Impact Factor: 4.5**]

- Ecker A, Simma O, Hoelbl A, **Kenner L**, Beug H, Moriggl R, Sexl V The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. ***Frontiers in Bioscience-Landmark*** 14:2944-2958 2009 [**Impact Factor: 3.3**]

- Eferl R, Hasselblat P, Rath M, Popper HH, Zenz R, Komnenovic V, Idarraga M, **Kenner L**, and Wagner EF Development of Pulmonary Fibrosis through a Pathway Involving the Transcription Factor Fra-2/AP-1. ***PNAS*** 105:10525-30 2008. [**Impact Factor: 9.7**]

- Meixner A, Zenz R, Schonthaler HB, **Kenner L**, Scheuch H, Penninger JM, Wagner EF. Epidermal JunB represses G-CSF synthesis and controls hematopoiesis and bone formation. ***Nat. Cell Biol*** 10:1003-11 2008. [**Impact Factor: 20.8**]

- Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin-Lanneree S, **Kenner L**, Kerenyi M, Yahiaoui S, Gouilleux-Gruart V, Gondry J, Benit L, Dusanter-Fourt I, Lassoued K, Valent P, Moriggl R, Gouilleux FH Oncogenic Kit controls neoplastic mast

cell growth through a Stat5/PI 3-kinase signaling cascade. ***Blood*** 112: 2463-73 2008 [**Impact Factor: 9.1**]

- Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, **Kenner L,** Komnenovic V, Scheuch H, Beug H, and EF Wagner p38a is essential for postnatal mouse development and suppresses cell proliferation by antagonizing the JNK/c-Jun pathway. ***Nat Genet*** 39:741-9 2007 [**Impact Factor: 35.2**]

- Staber P, Vesely P, Haq N, Ott R, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenja A,. Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg D, **Kenner L,** and Hoefler G. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signalling The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. ***Blood.*** 110: 3374-83 2007 **[Impact Factor: 9.1]**

- Staber PB, Noehammer C, Durkop H, Schauer S, **Kenner L**, Linkesch W, and Hoefer G. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. ***Leuk Res*** 30:343-8 2006 [**Impact Factor: 2.8**]

- Moriggl R, Sexl V, **Kenner L**, Stangl K, Duntsch Ch, Ecker A, Gingras S, Bauer A, Piekorz R, Hoffmeyer A, Wang D, Wagner EF, Ihle JN, and Beug H. Stat5 tetramers control cell-cycle progression and multi-lineage leukemia. ***Cancer Cell*** 7: 87-99 2005 [**Impact Factor: 24.7**]

- Zenz R, Eferl R, **Kenner L,** Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, and Wagner EF Arthritis caused by inducible epidermal deletionof Jun proteins. ***Nature*** 437: 369-75 2005 [**Impact Factor: 38.2**]

- **Kenner L***, Hoebertz A*, Eferl R, Beil FT, Amling M, Keon N, Schorpp-Kistner M, Angel P and Wagner EF Reduced bone formation and severe osteoporosis in mice lacking JunB. ***J Cell Biol*** 164: 613-623 2004 [**Impact Factor: 10.8**]*equally contributed

- Meixner A, Karreth F, **Kenner L**, and Wagner EF JunD regulates lymphocyte proliferation and T helper cell cytokine expression. ***EMBO J*** 23: 1325-1335 2004 [**Impact Factor: 9.8**]

- Eferl R, Hoebertz A, Beil FT, Amling M, **Kenner L**, and Wagner EF The Fos-related antigen Fra-1 is an activator of bone matrix formation. ***EMBO J*** 23: 2789-2799 2004 [**Impact Factor: 9.8**]

- Eferl R, Ricci R., **Kenner L**, Zenz R, David JP, Rath M, and Wagner EF Liver tumor development: c-Jun antagonizes the pro-apoptotic activity of p53. ***Cell*** 112:181-192 2003 **[Impact Factor: 32.0]**

- Zenz R, Scheuch H, Martin P, Frank C, Eferl R, **Kenner L**, Sibilia M, and Wagner EF C-Jun regulates eyelid closure and skin tumor development through EGFR signaling. ***Dev Cell*** 4: 879-889 2003 [**Impact Factor: 12.9**]

- **Kenner L***, Szremska AP*, Weisz E*, Ott RG, Passegué E, Artwohl M, Freissmuth M, Stoxreiter R, Theussl HC, Parzer S, Moriggl R, Wagner EF and Sexl V JunB inhibits proliferation and transformation in B-lymphoid cells. ***Blood*** 102: 4159-4165 2003 [**Impact Factor: 9.1**] *equally contributed.

- Melinz K, Bonelli RM, Niederwieser G, **Kenner L**, Reisecker F Primary high-grade B-cell lymphoma of the CNS. Case report and review of the literature. ***Nervenarzt*** 73: 779-84 2002 [**Impact Factor: 0.8**]
- Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, **Kenner L**, Kleinert R, Prinz M, Aguzzi A, Denk H p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. ***Am J Pathol*** 160: 255-63 2002 [**Impact Factor: 4.5**]
- Zollner G, Fickert P, Zenz R,. Fuchsbichler A, Stumptner C, **Kenner L**, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K and Trauner M Hepatobiliary Transporter Expression in Percutaneous Liver Biopsies of Patients with Cholestatic Liver Diseases. ***Hepatology*** 33: 633-46 2001 [**Impact Factor: 12.0**]
- Bonelli RM, **Kenner L.**, Gruber A, Reisecker F, Költringer P Compactotomy in Huntington's chorea. ***Med Hypotheses*** 57: 491-6 2001 [**Impact Factor: 1.1**]
- Felsner P, Steinschifter W, Fischer M, Eferl R, **Kenner L**, Zatloukal K, Lahousen M., Schauenstein E, and Schauenstein K. The tumor associated shift in Immunoglobulin G1/G2 is expressed at the messenger RNA level of peripheral blood B lymphocytes of human cancer patients. ***Cancer*** 88: 461-7 2000 [**Impact Factor: 5.2**]
- Obermayer-Pietsch BM, Frühauf GE, Chararas K, Mikhail-Reinisch S, Renner W, Berghold A., **Kenner L**, and Lackner C Association of the Vitamin D Receptor Genotype "BB" with Low Bone Density in Hyperthyroidism. ***J Bone Miner Res.*** 15: 1950-5 2000 [**Impact Factor: 6.1**]
- Bonelli RM, Gruber A, **Kenner L**, Költringer P, Reisecker F Reversible Huntington's Disease - lesion to the globus pallidus? ***Lancet*** 353: 240-241 1999 [**Impact Factor: 39.0**]
- Bonelli RM, Bonelli J, Költringer P, Kotter M, **Kenner L** Psychiatrists' attitudes to euthanasia. ***Lancet*** 353: 243-244 1999 [**Impact Factor: 39.0**]
- **Kenner L,** Sill H, Beham-Schmid C, Hulla W, Kroisl P, Kerbl R, Schmidt HH., Winter E., and Hoefler G. ABL amplification in a patient with lymphoid blast crisis of chronic myelogenous leukemia. ***Virchows Arch*** 434: 255-257 1999 [**Impact Factor: 2.7**]
- **Kenner L.**, Zatloukal K., Stumptner C., Eferl R., and Denk H. Altered microtubule-associated tau messenger RNA isoform expression in livers of griseofulvin- and 3,5-diethoxycarbonyl-1, 4-dihydrocollidine-treated mice. ***Hepatology*** 29(3): 793-800 1999 [**Impact Factor: 12.0**]
- **Kenner L.**, Schwarzl F., Moshammer H., Haas F., Höfler G., and Pierer G. Venous thrombosis in a replanted finger with underlying factor V Leiden mutation. ***Br J Plast Surg*** 51:57-58 1998 [**Impact Factor: 1.29**]
- El-Shabrawi Y., Langmann G, Hutter H, **Kenner L**., Hoefler G Comparison of current methods and PCR for the diagnosis of metastatic disease in uveal malignant melanoma. ***Ophthalmologica*** 212(1): 80 1998 [**Impact Factor: 1.4**]
- Bonelli R, Költringer P, **Kenner L**, Reisecker F. Reversible Chorea Huntington disease? ***Lancet*** 352(9139): 1520-1521 1998 [**Impact Factor: 39.0**]
- Fickert P, Ramschak H, **Kenner L**, Höfler G, Hinterleitner TA, Petrisch W, Krejs GJ, and Stauber RE Brief report: Acute Budd-Chiari Syndrome with fulminant hepatitic failure in

a pregnant woman with factor V Leiden mutation. ***Gastroenterology*** 111: 1670-1673 1997 [**Impact Factor: 12.8**]

- Eferl R, Lehner M, **Kenner L**, Kapfer I, Gürtl B, and Zatloukal K. Evaluation of different standard types for quantitative reverse transcription polymerase chain reaction: possible pitfalls and strategies for avoidance. Elsevier Trends Journals, ***Technical Tips Online*** (http://tto.trends.com) TO1214 1997 **IF: not determined**

- **Kenner L**, Tilz GP Extended diagnostic possibilities for the diagnostis and differential diagnosis of autoimmune hepathopathies with the PCR. ***Wien Med Wochenschr*** 145: 151-152 1995 **IF: not determined**

- **Kenner L**, El Shabrawi Y, Höfler G, Winter E, and Horina J Polymerase chain reaction for the diagnosis of viral Hepatitis C in clinical medicine. ***Nephron*** 69: 180 1995 **IF: not determined**

- Höfler G, Forstner M, McGuiness MC, Hulla W, Hiden M, Krisper P, **Kenner L**, Ried T, Lengauer C, Zechner R, Moser H, and Chen GL cDNA cloning of the human peroxisomal enoyl-CoA hydratase: 3-hydroxyacyl-CoA dehydrogenase bifunctional encyme and location to chromosome 3q26.3-3q28: a free left *Alu* Arm is inserted in the 3' noncoding region. ***Genomics*** 19: 60-67 1994 [**Impact Factor: 3.0**]

- Popper HH, Wirnsberger G, El-Shabrawi Y, Wöckel W, Höfler G, **Kenner L**, Jüttner-Smolle FM, und Pongratz-Röger MG HPV-detection with *in situ*-hybridisation and PCR in squamouse-cell papillomas of the bronchial mucosa. ***Hum Pathol*** 25: 1991-1997 1994 [**Impact Factor: 2.8**]

- **Kenner L**, El Shabrawi Y, Hutter H, Forstner M, Zatloukal K, Höfler G, Preisegger KH, Kurzbauer R, and Denk H Expression of three and four repeat tau isoforms in non-neural murine tissues. ***Hepatology*** 20: 1086-1089 1994 [**Impact Factor: 12.0**]

- Radner H., El Shabrawi Y, Eibl RH, Brüstle O, **Kenner L,** Kleihues P, and Wiestler OD Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose. ***Acta Neuropathol*** 86: 456-465 1993 [**Impact Factor: 9.7**]

- Horina J, Wirnsberger G, **Kenner L**, Holzer H, and Krejs GJ Increased susceptibility for cyclosporin induced hepatotoxicity in kidney graft recipients with viral hepatitis C. ***Transplantation*** 56: 1091-1094 1993 [**Impact Factor: 3.7**]

Review Articles (9)

Cumulative Impact Factor Total:	**40.625**
(2008 up to present, only reviews counted)	
Cumulative Impact Factor **2012:**	**2.116**
Cumulative Impact Factor **2011:**	**17.528**
Cumulative Impact Factor **2010:**	**6.774**
Cumulative Impact Factor **2009:**	**6.462**
Cumulative Impact Factor **2008:**	**7.965**

Reviews after the Habilitation (RA-1 to RA-9)

- Hopfinger G, Griessl R, Sifft E, Taylor N, **Kenner L**, Greil R, Merkel O. Novel treatment avenues for peripheral T-cell lymphomas. Expert Opin. Drug Dis. 12:1149-63 2012 [**Impact Factor: 2.3**]

- Merkel O, Hamacher F, Sifft E, **Kenner L**, Greil R; European Research Initiative on Anaplastic Large Cell Lymphoma. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. ***Mol Cancer Ther*** 10(7):1127-36 2011 [**Impact Factor: 5.6**]

- Leeb C, Jurga M, McGuckin C, Forraz N, Thallinger C, Moriggl R, **Kenner L**. New perspectives in stem cell research: beyond embryonic stem cells. ***Cell Prolif*** 44:9-14 2011 [**Impact Factor: 2.3**]

- Merkel O, Kenner L and Turner SD Anaplastic large cell lymphoma: the current state of play from a European prospective as presented at the second annual meeting of the European Research Initiative on ALCL, **25,** 1795–1796 2011 ***Leukaemia*** [**Impact Factor: 10.2**]

- Leeb C, Jurga M, McGuckin C, Moriggl R, **Kenner L** Promising new sources for pluripotent stem cells. ***Stem Cell Rev*** 6(1):15-26 2010 [**Impact Factor: 4.5**]

- Vesely PW, Staber PB, Hoefler G, **Kenner L** Translational regulation mechanisms of AP-1 proteins. ***Mutat Res Rev Mutat*** 682(1):7-12 2009 [**Impact Factor: 6.5**]

- Pflegerl P, Keller T, Hantusch B, Hoffmann TS, **Kenner L**H Stem cells - cloning, plasticity and bioethics. ***Wien Med Wochenschr.*** 158:493-502 2008 **IF: not determined**

- Kornfeld JW, Grebien F, Kerenyi MA, Friedbichler K, Kovacic B, Zankl B, Hoelbl A, Nivarti H, Beug H, Sexl V, Muller M, **Kenner L**, Mullner EW, Gouilleux F, Moriggl RH The different functions of Stat5 and chromatin alteration through Stat5 proteins. ***Frontiers in Bioscience-Landmark*** 13:6237-54 2008 [**Impact Factor: 3.3**]

- Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, **Kenner L**, Tschachler E, Wagner EF Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. ***Arthritis Research & Therapy*** 10:201 2008 [**Impact Factor: 4.3**]

Book Chapters (B-1 to B-2, after Habilitation)

- **Kenner L** Das Klonschaf ist tot- es lebe das Klonen? In: F. Bydlinski/Th. Mayer-Maly (eds.) **Rechtsethik** Springer Wien-NewYork, Vol. 4, 43-66, 2008.

- **Kenner L** Anhörung des Ausschusses für Bildung, Forschung
  Und Technikfolgenabschätzung zum Thema „Stammzellforschung“
  Stellungnahme von Prof. Dr. Lukas Kenner 2007: /www.bundestag.de/ausschuesse/a18/ anhoerungen/ stammzellforschung/ stellungnahmen/ 193s.pdfU

Collaborations of Lukas Kenner

The group of **L. Kenner** holds long term national and international collaborations. These collaborations are essential for joint publications, but also successful grant money attraction. Laboratory members or our translation models are regularly sent to collaborators.

National

- **Zoran Culig**, Medical University Innsbruck, Urology Department, on IL-6/Stat3 signaling and invasion in prostate cancer.
- **Thomas Decker**, MFPL Vienna IFNAR in IBD
- **Uli Jäger**, MUV, Internal Medicine Department I, Role of PDGFRB in NPM-ALK lymphomagenesis.
- **Helmut Klocker,** Medical University Innsbruck, Urology Department, on the role of IGF-1 axis and MID-1 in mouse and human prostate cancer.
- **Hannes Neuwirth,** Medical University Innsbruck, Internal Medicine Department IV, on Stat3 signaling and invasion in renal carcinogenesis.
- **Mathias Müller,** University of Veterinary Medicine, Vienna, Tyk2 in IBD.
- **Josef Penninger**, IMBA Vienna, on the role of RANKL in MMTV induced breast Cancer tumor induction.
- **Thomas Rülicke** University of Veterinary Medicine, Vienna, Phenotyping of heart disease in transgenic mouse models.
- **Maria Sibilia,** CCC, MUV, EGFR in animal models for colitis.
- **Christian Seiser**, Max F. Perutz Laboratories, Medical University of Vienna, Vienna Biocenter, on HDAC regulated stem cell differentiation and tumorigenesis
- **Veronika Sexl,** University of Veterinary Medicine, Vienna, CDK6 in NPM-ALK transgenic mice.
- **Peter Valent**, MUV, Internal Medicine Department I, Imatinib treatment of NPM-ALK transgenic mice.

International

- **Sebastian Bauer**, Institute of Cancer Research of the Internal Medicine Department, University Duisburg-Essen, Germany, on GIST mutations of c-KIT in human GIST tumor formation.
- **Fabrice Gouilleux**, University Picardie Jules Verne, INSERM 0351, Amiens, France, on GIST and activated forms of Stat3.
- **Greg Hannon**, Cold Spring Harbor Laboratory (CSHL), on the role of miRNA in cordblood stemcell differentiation.
- **Suzanne Turner,** University of Cambridge UK, on tumor –stroma interactions and stem cells pathology in ALCL
- **Konrad Hochedlinger**, Harvard Stem Cell Institute, Cambridge, MA, U.S.A., on stem cell induction using viral vectors.
- **Giorgio Inghirami**, Center for Experimental Research and Medical Studies, University of Torino, Italy, on the role of AP-1 in NPM-ALK induced human- and mouse lymphomagenesis.
- **Colin McGuckin** CTI, Lyon, France, on Jak/Stat pathway in stem cell differentiation and tumorigenesis.
- **Mark Parthun,** Ohio State University, Columbus, Characterisation of HAT-/-.
- **Mariusz Ratajczak**, University of Luiseville, Stem cell Institute at James Brown Cancer Center, KY, USA, on cancer stem cell induced rhabdomyosarcoma development.
- **Raffaella Sordella**, (CSHL), on the role of IL-6 in lung carcinogenesis.
- **William Tse,** West Virginia University School of Medicine, Morgantown, USA, AF1q in breast cancer metastasis.
- **Jan Tuckermann**, University of Ulm, on transgenic Stat5 and GR mice in inflammatory diseases.

Teaching at German speaking universities (therefore this part is provided in German):

I) Lectures and Education of Students
My techinfg since includes approximately 50 hours per semster and consists among other things of lectures on the molecular basis of tumor development and the production and analysis of transgenic mouse models at the Clinical Institute of Pathology (CIP) of the MUV. Furthermore LK heads teaches autopsy courses for medical students at the CIP/MUV and internships in pathological histology. Since 2011 LK performs the 2-hour lecture "phenotyping of Biomodels" at the University of Veterinary Medicine for the Master's degree program in biomedical / Biotchnologie Program. Together with Prof. Renate Kain, LK organized the 2013 international TransVir Winter School "Histology and Histopathology for Translational Scientists" at the CIP for for students of comparative pathology (13-15.2.2013). In the context of studying veterinary medicine at the University of Veterinary Medicine LK holds the laboratory animal pathology lectures staring with the summer-semester 2013 for the Advanced Module "laboratory animal medicine" At the CIP. LK is involved in the training of junior doctors in macroscopy, histopathology and cytology. Furthermore LK plans together with Prof. Tamas Nagy (Institute for Laboratory Animal Pathology, Giorgia State University, USA), a 4-day course in laboratory animal pathology and translational pathology for students in the fall of 2013 in close cooperation with the University of Veterinary Medicine (Prof. Thomas Rülicke, Prof. Peter Schmidt). In his working group LK has until now a postdoc (Pamina Pflegerl) a PhD student (Daniela Laimer) and four graduate students (Amenitsch Lena, Nora Dzuck, Lisa Grabner and Merima Herac) trained and supervised. His working group actively participates in events such as the "Young Scientists Association" with contributions of their own part and his student Daniela Laimer and Jan Pencik are also educated from a doctoral program that MUV which is headed by Prof. Stefan Boehm.

II) Own seminar lectures, guest speakers, university teaching and educational activities
LK has organized a monthly seminar series "Cheese and Crackers" at the CIP with numerous prominent lecturers, mainly from Austria, but also from abroad since 2007 (M. Müller (University of Veterinary Medicine); B. Dickson (IMP); M. Sebilia (CCC of MUV); A. Rees (Marie Curie Chair), J. Penninger (IMBA) and many others. At the LBI-CR **LK** is involved in the organisiation of seminars of world-class researchers for the series at the LBI-CR (see http://lbicr.lbg.ac.at/en/annual-report). **LK**, together with Prof. Suzanne Turner (Cambridge University, UK), and Prof. Olaf Merkel (University of Heidelberg) founded 2009 the scientific society ERIA (European Research initiative for ALCL) http://www.erialcl.net to explore the basics of ALK related diseases. **LK** co-organizes every year the annual ERIA conferences since 2010 (2010 in Salzburg/Austria, 2011 in Vienna/Austria, 2012 in Cambridge/UK and 2013 in Heidelberg/Germany). **LK** takes part in the monthly meetings of the" Bioethics Commission of the Prime Minister" in the Chancellery in Vienna. **LK** has significantly contributed to the vote of the "Bioethics Commission of the Prime Minister" to reform the law reproductive Medicine. Upon invitation by the Ministry of Science and the Pharma/Biotechindustry LK participated actively in the revisions of the Animal-experiment directives in Austria.

III) Supervision of PhD and Master Students
Currently supervised PhD students:

Name)	*Short-titel of the Projekts*
Jan Pencik (ongoing) *	Analysis of the IL-6/Stat3 signalling in Prostatecancer
Osman Aksoy (ongoing)	The Role of µCrystallin for the Progression of Prostatecancer
Matthias Schedl (ongoing)	Investigation in the use of zebrafish to study organ regeneration, stem cell biology and tumor- induced angiogenesis

- Jan Pencik got the prize der **Europäischen "Society for Urological Research (ESUR)"** 2010 for his Presentation "**Stat3 a tumor suppressor in PTEN$^{\Delta PEC}$ induced prostate cancer?**". In adddition he got the price of the **Comprehensive Cancer Center (CCC)** in 2011 for his work **"NFkB activity modulates the Oncogenic potential of Stat3 in**

Prostate Cancer Development" and the **Science Prize of the French "Association pour la Recherche sur les tumeurs de la Prostate (ARTP)" 2011** for his presentation **"Stat3 is a suppressor of the tumor progression and tumor immunity in prostate cancer."**

-

Previously supervised PhD students

Name	*Short-titel of the Projekts*
Daniela Laimer*	Identification of a rational and highly effective therapy to treat NPM-ALK driven lymphomas

** Daniela Laimer got the **first Prize** for the **best presentation at the PhD Symposium of the 7th YSA at the MUV**, Vienna, 6/11 **"Identification of a rational and highly effective therapy to treat NPM-ALK driven lymphomas"** and the **first Prize for the best poster at the microenvironment, vasculature and Metastasis symposium, the CCC** for the MUV her presentation **"PDGFRB blockade is a rational and effective therapy for NPM-ALK lymphomas"** Vienna, 10/2012.

Previously supervised Master/Diplomastudents

Name)	*Short-titel of the Projekts*
Lena Amenitsch (ongoing)	Characterization of imatinib treated and untreated *CD4*-NPM-ALK and *CD4*-NPM-ALK-*CD4*$^{\Delta\Delta JUN}$ lymphomas regarding differences in stromal markers and motility proteins
Tine Vollheim (ongoing)	cJun is a tumor suppressor in prostate cancer
Tanja Limberger (ongoing)	NPM-ALK lymphoma-tumor stroma interactions in vivo and in vitro

Previously supervised Master- or Diploma students

Name)	*Short-titel of the thesis*
Nora Dzuck	Effects of cJun and JunB in Prostate Cancer
Lisa Grabner	MicroRNA-155 and its role in anaplastic lymphoma kinase (ALK) negative anaplastic large cell lymphoma (ALCL)
Merima Herac	Senescence signaling pathway in prostate cancer-a retrospective immunohistochemical analysis performed on multi tissue array

In addition to practical techniques **LK** intensively trained the above students in the theoretical principles of molecular pathology.

Further support for internships and university students:

(i) WS 2005 SS 2006 1hr/week Pathology and Histological exercises, Part I.
(ii) WS 2005 - SS 2006 8hrs/week Pathological-Anatomical clerkship.
(iii) WS 2006 - SS 2007 SemWo 4hrs/week Pathological Histology Exercises Part II.
(iv) SS 2006 2hrs/week Refresher of Pathological Anatomy and Histology.
(v) WS 2006 - SS 2007 0.28hrs/week Seminar transgenic mouse models
(vi) WS 2006 - SS 2008 2hrs/week Pathological Histology internship in block 8,
(vii) WS 2007 - SS 2008 0.39hrs/week Special diagnostic skills in pathology.
(viii) SS2008-SemWo WS2008 4hrs/week demonstration of pathological cases.
(ix) WS 2009 - SS 2011 4hrs/week Lecture on stem cells in medicine
(x) SS-2009 SS2010- 4hrs/week Lecture on production and analysis of transgenic mouse models
(xi) SS 2009-2010 4hrs/week Lecture and exercise: practical pathology.
(xii) WS 2011 4hrs/week Lecture on the molecular basis of tumor development

(xiii) WS 2011 - 2013 2hrs/week Lecture, phenotyping in pathology: lecture and practical erxersice.
(xiv) SS 2011-WS2012 10hrs/week Lecture and practical exercise in pathology
(xv) SS 2011 SS2012 4hrs/week Lecture: "phenotyping of Laboratory animals"; pathology for college students of the Veterinary Medicine university.

Supervision of University Staff (Biomedical research assistance (BMA))

2005-2007: Mag. Ricarda Brandes (BMA)
2005-2013: Mag. Michaela Schlederer (BMA)
2007-2013: Mag. Elisabeth Gurnhofer (BMA)
2012-2013: Mag Jelena Marjanovic (BMA)

Vienna, February 2013 Lukas Kenner (counts as signed)